| scholarly article | Q13442814 |
| P2093 | author name string | Thomas C Hamilton | |
| Anthony T Yeung | |||
| Rudi Bao | |||
| Muthu Selvakumaran | |||
| Debra A Pisarcik | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| cytotoxicity | Q246181 | ||
| cisplatin | Q412415 | ||
| P304 | page(s) | 1311-1316 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines | |
| P478 | volume | 63 |
| Q35917703 | Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy |
| Q37365005 | Antisense oligonucleotide suppression of human IGF-1R inhibits the growth and survival of in vitro cultured epithelial ovarian cancer cells |
| Q38228349 | Apoptosis and molecular targeting therapy in cancer |
| Q38720813 | Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma |
| Q37397607 | BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? |
| Q26784289 | Biomarkers of head and neck cancer, tools or a gordian knot? |
| Q36370912 | CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene |
| Q92504315 | Capsaicin enhances erlotinib-induced cytotoxicity via AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cells |
| Q28073246 | Chemoresistance and targeted therapies in ovarian and endometrial cancers |
| Q33788519 | Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer |
| Q35402288 | Cisplatin loaded albumin mesospheres for lung cancer treatment |
| Q24628775 | Cisplatin ototoxicity and protection: clinical and experimental studies |
| Q37328494 | Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck |
| Q42361422 | Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies. |
| Q28468348 | Collagen gel droplet-embedded culture drug sensitivity testing in squamous cell carcinoma cell lines derived from human oral cancers: Optimal contact concentrations of cisplatin and fluorouracil |
| Q35944751 | Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro. |
| Q52721498 | Current Opinions on Chemoresistance: An Overview. |
| Q36576047 | DNA interstrand crosslink repair and cancer |
| Q84630032 | DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy |
| Q37160598 | DNA repair proteins as molecular targets for cancer therapeutics |
| Q92766578 | Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression |
| Q34722650 | Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells |
| Q34468400 | Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines |
| Q39711077 | Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. |
| Q34437369 | Drug resistance in cancer: an overview. |
| Q34278209 | ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy |
| Q89113789 | ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer |
| Q36994946 | Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells |
| Q45070718 | Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review |
| Q36244040 | Emodin affects ERCC1 expression in breast cancer cells |
| Q40092976 | Establishment of a new human glioblastoma multiforme cell line (WJ1) and its partial characterization |
| Q41002840 | Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma |
| Q37666690 | Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion |
| Q42147973 | Expression of porcine protegrin-1 in Pichia pastoris and its anticancer activity in vitro |
| Q37069628 | Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy |
| Q36457037 | From the bench to the bed: individualizing treatment in non-small-cell lung cancer |
| Q36586981 | Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells |
| Q44718934 | Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36291188 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo |
| Q48428390 | Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells |
| Q40019078 | Growth-inhibiting and apoptosis-inducing effects of Tanshinone II A on human gastric carcinoma cells |
| Q24814636 | Haploinsufficiency for BRCA1 is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes |
| Q54374388 | Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue. |
| Q35892472 | Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro |
| Q37688903 | Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. |
| Q36557333 | Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study |
| Q47128274 | Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells |
| Q33867457 | Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer |
| Q42566962 | Interrogation of Nucleotide Excision Repair Capacity: Impact on Platinum-Based Cancer Therapy |
| Q84465873 | Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy |
| Q38932916 | L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells. |
| Q42378307 | Liquiritin induces apoptosis and autophagy in cisplatin (DDP)-resistant gastric cancer cells in vitro and xenograft nude mice in vivo |
| Q37213050 | Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment |
| Q34285363 | Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. |
| Q35872796 | Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy |
| Q37282213 | Monofunctional and higher-valent platinum anticancer agents. |
| Q36387554 | NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. |
| Q85009488 | Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis |
| Q37461061 | Novel strategies for reversing platinum resistance |
| Q28382823 | Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 |
| Q36740692 | PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. |
| Q36062762 | Personalized therapy for urothelial cancer: review of the clinical evidence |
| Q47563582 | Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. |
| Q38460343 | Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. |
| Q28583407 | Preincision complex-I from the excision nuclease reaction among cochlear spiral limbus and outer hair cells |
| Q93157621 | Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells |
| Q34086636 | Prognostic biomarkers in ovarian cancer |
| Q35730375 | Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer |
| Q36891437 | Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden |
| Q38019607 | Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. |
| Q40008844 | Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis |
| Q39468003 | Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia |
| Q39102558 | The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs |
| Q36510142 | The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro |
| Q41762961 | The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy |
| Q53775795 | The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells. |
| Q38810214 | The interplay between autophagy and apoptosis induced by tanshinone IIA in prostate cancer cells |
| Q33421515 | The role of Bcl-x(L) protein in nucleotide excision repair-facilitated cell protection against cisplatin-induced apoptosis |
| Q94215766 | miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5 |
Search more.